Common TitleARIEL
Official Title A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age
Phase Phase II
ClinicalTrials.gov NCT00919854
Treatments
Darunavir
Darunavir
Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)Categories Resistance/Virological FailurePediatricsTreatment-Experienced
Funding
IndustryTibotec Pharmaceuticals, Ireland
References
- Violari A, Bologna R, Kumarasamy N, et al. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. Pediatr Infect Dis J. 2015;34:e132-7.